12 projects
Status
Domain
Organization Type
inhibition of inflammation
Acute lung injury is a therapeutically high unmet need indication caused by uncontrolled inflammation with high expression of mediators to promote inflammation, called cytokines. If not reversed, it leads to acute respiratory distress syndrome (ARDS) as major reason for death in patients with COVID-19. Nekonal validated specific acting compounds and biomarkers to detect and stopp uncontrolled hyperimmune activation at early stage.
Phylodynamic real-time monitoring of SARS-CoV-2 genomes
The current Covid-19 pandemic caused by the SARS-CoV-2 visus is an extreme world wide challenge to mankind's health. Current approaches to manage this challenge rely on reliable testing as well as the development of vaccination which both depend on the stability of specific sequences of the viral genome. Sequencing of viral genomes from patient samples provides deep insights on pathogen dynamics in terms of phylogeny and evolution allowing for spreading analysis and adaptation of molecular diagnostic and prevention strategies. Hence, the automatic dynamic analysis of data derived from v...
Multi-omics evaluation of microbial co-infection as marker of COVID-19 severity -(CO-INFECTOMICS)
The main goal of this project is to understand if SARS-CoV2 co-infections are a predictive marker of disease severity in the Luxembourgish population. To achieve this, the study will compare the respiratory and stool samples of mild and severe SARS-CoV2 positive patients. Using metagenomics and metatranscriptomics, microbial profiles of the respiratory and intestinal tracts will be investigated, with a specific attention for co-infections. Moreover, individual microbial profiles will be correlated to the health parameters and immune response. We hope that the CO-INFECTOMICS project will ena...
Docking and binding affinity prediction for candidate small molecule inhibitors of COVID-19 prote...
Currently no vaccine or sufficiently validated pharmacological treatment is available for COVID-19. Drug-based strategies to reduce the viral load in patients with severe forms of COVID-19 include the repurposing of existing small molecule compounds that inhibit the activity of key viral proteins, or human proteins involved in mediating the viral entry or release from the host cell. However, so far, the identified small molecule inhibitors for SARS-CoV-2 target proteins studied in-vitro have significant limitations in terms of their binding affinity to the target, their bioavailability in t...
